<DOC>
	<DOC>NCT00446069</DOC>
	<brief_summary>The purpose of the study is to determine the effect of EgaletÂ® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.</brief_summary>
	<brief_title>A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<criteria>The patient has stable strong opioid use equipotent to 30240 mg oral morphine sulphate daily for a minimum of 2 weeks prior to entering the runin phase. The patient has opioidsensitive pain caused by active cancer. The patient is aged minimum 18 years. The patient has a life expectancy less than 2 months. The patient has received chemotherapy or radiation therapy less than 4 weeks prior to entering runin phase Patients with medical conditions contraindicating morphine treatment The patient has hepatic disease or impaired kidney function The patient is taking monoamine oxidase inhibitors (MAOIs) or has taken a MAOI within two weeks prior to entering baseline. The patient is taking other opioid agonists or antagonists, zidovudine or cimetidine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>